Chapters

Transcript

Video

Do you use different LDL-C levels in persons with diabetes to justify initiation of PCSK9 inhibitors? Is the presence of ACS required or symptomatic ASCVD required to triage them into PCSK9-based treatment?

Do you use different LDL-C levels in persons with diabetes to justify initiation of PCSK9 inhibitors? Is the presence of ACS required or symptomatic ASCVD required to triage them into PCSK9-based treatment?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Sergio Fazio, MD

Sergio Fazio, MD

Director, Center for Preventive Cardiology Professor of Medicine Division of Cardiovascular Medicine School of Medicine  Oregon Health Sciences University (OHSU) Portland, OR